|
Orthologous residues
|
|
Lasp‑1 (human): Y171‑p, Lasp‑1 (mouse): Y173‑p, Lasp‑1 (rat): Y173‑p, Lasp‑1 (rabbit): Y174‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
leukemia, chronic myelogenous leukemia
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast), COS (fibroblast), K562 (erythroid)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Abl (human)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, modification site within consensus motif, phospho-motif antibody, co-immunoprecipitation, genetic knockout/knockin of upstream enzyme, transfection of wild-type enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
Abl iso2 (human)
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
apoptosis, induced
|
